0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover0.00%IV-51.82%PremiumJan 17, 2025Expiry Date5.12Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.94Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Hillman Solutions Stock Discussion
• $Fortinet (FTNT.US)$ : BMO Capital Upgrades to Outperform from Market Perform - PT $350 (from $325)
• $Microchip Technology (MCHP.US)$ : Stifel Upgrades to Buy from Hold - PT $75 (from $70)
• $Ovintiv (OVV.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $64 (from $56)
• $Riot Platforms (RIOT.US)$ : Compass Point Upgrades to Buy from Neutral - PT $14 (from $30)
• $Snowflake (SNOW.US)$ : Jefferies Upgrades to Buy f...
• $American Airlines (AAL.US)$ : JP Morgan Upgrades to Neutral From Underweight - PT $26 (from $18)
• $The AZEK (AZEK.US)$ : Citigroup Upgrades to Buy from Neutral - PT $30 (from $36)
• $BXP Inc (BXP.US)$ : Mizuho Upgrades to Buy from Neutral - PT $135 (from $120)
• $Dow Inc (DOW.US)$ : Citigroup Upgrades To Buy From Neutral - PT $82 (from $70)
• $The Kroger (KR.US)$ : Exane Upgrades to Neutral from Underperform - PT $60
• $Milestone Pharmaceuticals (MIST.US)$ : Piper S...
• $Antares Pharma (ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology (SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma (AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics (BCTX.US)$ +6% (presents development details of...
No comment yet